SAT02 - MERZ PHARMACEUTICALS GMBH
MANAGEMENT OF FEMALE HAIR LOSS: EMOTIONAL IMPACT, DIAGNOSTIC TOOLS AND THERAPEUTIC APPROACH
Chair: R. M. Trüeb (Zurich, Switzerland)
Co-Chair: R. Hoffmann (Freiburg, Germany)

SAT02.1 HAIRY PROBLEMS – PSYCHOSOCIAL ASPECTS OF HAIR LOSS U. Gieler (Giessen, Germany)	16:45

SAT02.2 SYSTEMATIC APPROACH TO DIFFUSE HAIR LOSS IN WOMEN R. M. Trüeb (Zurich, Switzerland)	17:05

SAT02.3 COMPUTER SOFTWARE TRICHOSCIENCE® (V-1.5) PROFESSIONAL DIAGNOSTIC PROGRAM FOR OFFICE BASED TRICHOLOGISTS V.P. Tkachev (Moscow, Russia)	17:25

SAT02.4 RANDOMIZED OPEN CLINICAL TRIAL ON THE EFFICACY OF A L-CYSTINE-MEDICINAL YEAST-PANTOTHENIC ACID AND B-VITAMIN (CYP)-BASED ACTIVE COMPOUND (PANTOVIGAR®) IN WOMEN WITH TELOGEN EFFLUVIUM T.V.Tsimbalenko, V.P.Tkachev, M.V. Khaldina, O.S. Panova (Moscow, Russia)	17:45

Q&A	18:05

Thursday September 18, 2008 – 13:00 – 14:30

SAT03 - GALDERMA
A NEW ERA IN ACNE MANAGEMENT HOW TO INTEGRATE NEW DRUGS INTO PRACTICE
Chair: H. Gollnick (Magdeburg, Germany)
Co-Chair: B. Dréno (Nantes, France)

SAT03.1 FROM THEORY TO PRACTICE: ACNE PATHOPHYSIOLOGY AND DRUG TARGETING
B. Dréno (Nantes, France)

SAT03.2 THE ROLE OF RECENTLY APPROVED ACNE DRUGS
V. Bettoli

SAT03.3 CONSIDERATIONS IN DEVELOPING TOPICAL ACNE PRODUCTS
C. Loesche

SAT03.4 FIXED-COMBINATION OF RETINOID-BPO: AN ADVANCE IN TOPICAL ACNE THERAPY
H.Gollnick (Magdeburg, Germany)

SAT04 – VICHY
MEN’S SKIN: IMPROVING OUR KNOWLEDGE OF HEALTHY SKIN
Chair: A. Bouloc (France)
Co-chair: T. Michaud (France)

SAT04.1 More and more men seeking dermatological advice
T. Michaud (France)

SAT04.2 Male canons of beauty
M. Landau (Israel)

SAT04.3 Properties of men’s skin
M. Picardo (Italy)

SAT04.4 Clinical aging index in men of different ethnicities
R. Bazin (France)

SAT04.5 Active cosmetic ingredients for men skin care
S. Lischner (Germany)

Q&A
CONCLUSION

SAT05 – NOVARTIS PHARMA AG
NEW ADVANCES IN TOPICAL DRUG DELIVERY - TARGETED TO ACHIEVE IMPROVED EFFICACY IN SUPERFICIAL FUNGAL INFECTIONS
Chair: J.P. Ortonne (Nice, France)

SAT05.1INTRODUCTION J.P. Ortonne (Nice, France)	13:00

SAT05.2 FOOT MYCOSIS : FROM TINEA PEDIS TO ONYCHOMYCOSIS – THE NEED FOR EFFECTIVE MANAGEMENT H. C. Korting (Munich, Germany)	13:05

SAT05.3 LAMISIL (TERBINAFINE) - 20 YEARS OF PROVEN EFFICACY – VARIOUS FORMULATIONS AVAILABLE FROM ORAL TO TOPICAL B. Sigurgeirsson (Iceland)	13:15

SAT05.4 A BREAKTHROUGH TREATMENT FOR TINEA PEDIS : TOPICAL SINGLE-DOSE LAMISIL ONCE® T. Jones (Basel, Switzerland)	13:25

SAT05.5 EVIDENCE BASED MEDICINE ON TOPICAL ATHLETE FOOT THERAPIES J. P. Ortonne (Nice, France)	13:40

SAT05.6 A NOVEL TOPICAL FORMULATION OF TERBINAFINE FOR ONYCHOMYCOSIS (INVESTIGATIONAL): PHARMACOKINETICS & MICROBIOLOGY M. Ghannoum (Cleveland, US)	13:55

SAT05.7 INVESTIGATIONAL TERBINAFINE NAIL SOLUTION FOR ONYCHOMYCOSIS: CLINICAL DATA B. Sigurgeirsson (Reykjavik, Iceland)	14:10

Q & A	14:15

SAT06 – BASILEA PHARMACEUTICA INTERNATIONAL LTD
ALITRETINOIN : THE NEW THERAPY IN CHRONIC HAND ECZEMA
Co-Chairs: T. Ruzicka (Munich, Germany), F. Cambazard (St. Etienne, France)

SAT06.1 WELCOME & INTRODUCTION T. Ruzicka (Munich, Germany)	13:00

SAT06.2 CHRONIC HAND ECZEMA - A DISEASE WITH A SIGNIFICANT IMPACT ON HEALTH AND QUALITY OF LIFE T. Diepgen (Heidelberg, Germany)	13:10

SAT06.3 CURRENT TREATMENT STRATEGIES IN CHRONIC HAND ECZEMA – BENEFITS & LIMITATIONS R. Graham-Brown (Leicester, United Kingdom)	13:35

SAT06.4 ALITRETINOIN - A NEW, EFFECTIVE LONG-TERM TREATMENT FOR CHRONIC HAND ECZEMA J. Berth-Jones (Nuneaton, United Kingdom)	14:00

SAT06.5 Q&A All	14:25

SAT06.6 SUMMARY & CLOSE F. Cambazard (St. Etienne, France)	14:30

SAT07 – GENERAL TOPICS
THEORETICAL AND PRACTICAL TRAINING COURSE OF VARIOUS PEELS ACCORDING TO SPECIFIC SKIN CONDITIONS AND PROBLEMS
Glycolic peel, salicylic acid, pyruvic acid, trichloroacetic acid, Jessner peel, neck peel, hands peel, eyes and lips peel.
Chair: M. Belmontesi (Milan, Italy)
Co-Chairs: G. de Paoli Ambrosi (San Felice del Benaco, Italy), S. Truedsson (Oslo, Norway), M. Sokolowska-Wojdylo (Gdansk, Poland), E. Rumyantseva (Moscow, Russia)

SAT07.1 GENERAL OVERVIEW OF PEELING TECHNIQUES IN DERMATOLOGY.
M. Belmontesi (Milan, Italy)

SAT07.2 THE ELECTROCHEMICAL IMPACT OF ORGANIC ACIDS ON SKIN BIOLOGY
G. de Paoli Ambrosi (San Felice del Benaco, Italy)

SAT07.3 THEORETICAL AND PRACTICAL DEMONSTRATION IN TREATING THE MORE SEVERE SKIN PROBLEMS WITH TRICHLOROACETIC ACID.
S. Truedsson (Oslo, Norway)

SAT07.4 THEORETICAL AND PRACTICAL DEMONSTRATION IN TREATING COMEDONIC AND INFLAMMATORY ACNEIC LESIONS WITH A SALICYLIC ACID PEEL IN COMBINATION WITH TRIETHYLCITRATE AND ETHYL LINOLEATE.
M. Sokolowska-Wojdylo (Gdansk, Poland)

SAT07.5 THEORETICAL AND PRACTICAL DEMONSTRATION OF PEELS DEDICATED TO SPECIAL SKIN AREAS: NECK, HANDS, CONTOUR EYES (INCLUDING EYELIDS) AND LIPS.
E. Rumyantseva (Moscow, Russia)

SAT08 – LEO PHARMA
THE VALUE OF TOPICAL TREATMENT
Chair: K. Kragballe (Denmark)

SAT08.1 CHAIRMAN'S WELCOME K. Kragballe (Denmark)	13:00

SAT08.2 INTRODUCTION TO HEALTH ECONOMICS J.Lambert (Belgium)	13:05

SAT08.3 PATIENT SATISFACTION WITH TOPICAL TREATMENT OF PSORIASIS L. Kircik (United States) J. Hein Sindrup (Denmark)	13:25

SAT08.4 COSTS RELATED TO THE TREATMENT OF PSORIASIS M. Augustin (Germany)	13:45

SAT08.5 COST OF TREATING SCALP PSORIASIS K.Kragballe (Denmark)	14:10

SAT08.6 CHAIRMAN'S CLOSING REMARKS K. Kragballe (Denmark)	14:20

SAT09 – ABBOTT
PSORIASIS AND BEYOND: THE NEXT CLINICAL CHALLENGES
Chair: C. Griffiths (Manchester, United Kingdom)

SAT09.1 INTRODUCTION C. Griffiths (Manchester, United Kingdom)	13:00

SAT09.2 OPTIMIZING PSORIASIS MANAGEMENT W. Sterry (Berlin, Germany)	13:05

SAT09.3 ARE WE MAXIMIZING THE USE OF SYSTEMIC THERAPIES IN PSORIASIS? P. Van de Kerkhof (Nijmegen, The Netherlands)	13:30

SAT09.4 PSORIASIS PATIENTS: A LONG-TERM VIEW C. Griffiths (Manchester, United Kingdom)	13:45

SAT09.5 EXPLORING THE ROLE OF BIOLOGICS IN SEVERE DERMATOSES F. Kerdel (Miami, USA)	14:00

SAT09.6 CONCLUDING REMARKS C. Griffiths (Manchester, United Kingdom)	14:25

Thursday September 18, 2008 – 16:45 – 18:15 - Room 251

SAT10 – SCHERING PLOUGH
THE PSORIASIS (R)EVOLUTION 2005-2008
Chair: C. Paul (Toulouse, France)

SAT10.1 OPENING REMARKS
Chair: C. Paul (Toulouse, France)

SAT10.2 AGE OF ENLIGHTENMENT IN PSORIASIS
J. Barker (London, United Kingdom)

SAT10.3 EVOLUTION OF TREATMENT GOALS
K. Reich (Hamburg, Germany)

SAT10.4 ECONOMIC REVOLUTION
M. Augustin (Hamburg, Germany)

SAT10.5 EMBRACING CHANGE IN YOUR EVERYDAY PRACTICE
N. Shear (Toronto, Canada)

SAT10.6 QUESTION AND ANSWER (PANEL)

SAT10.7 CLOSING REMARKS
C. Paul (Toulouse, France)

SAT11 – LA ROCHE POSAY BIOMEDIC
WHAT’S NEW IN AESTHETIC DERMATOLOGY?
Chair: C. Roland Payne (United Kingdom)

SAT11.1 THE LHA-PEEL: A BREAKTHROUGH IN SUPERFICIAL CHEMICAL PEELING
M. Sanchez Viera (Spain)

SAT11.2 SUPERFICIAL PEELING AND COMBINED THERAPY IN AGING: “AN EUROPEAN ALGORITHM”
B. Dréno (France)

SAT11.3 THE SKIN SURFACE ANALYSER (SSA): “A LAB IN YOUR OFFICE” TO QUANTIFY AND FOLLOW THE EFFICACY OF AESTHETIC TREATMENTS.
P. Humbert (France)
D. Perrenoud (Switzerland)

SAT12 – PIERRE FABRE DERMATOLOGIE ESTHETIQUE
AESTHETIC DERMATOLOGY AND ETHIC
Chair: M. Gold (Nashville, USA)

SAT12.1 WELCOME AND INTRODUCTION O. Fontaine (Toulouse, France)	16:45

SAT12.2 AESTHETIC DERMATOLOGY STATE OF THE ART FOCUS ON PEELINGS AND FILLERS M. Gold (Nashville, USA)	16:50

SAT12.3 GLYTONE PHARMACEUTICAL DEVELOPMENT : FROM FORMULATION TO MEDICAL DEVICE S. Chesnoy (Toulouse, France)	17:10

SAT12.4 GLYTONE PEELINGS : CLINICAL AND BIOMETROLOGICAL RESULTS M. Baspeyras (Bordeaux, France)	17:25

SAT12.5 GLYTONE FILLERS : CLINICAL AND BIOMETROLOGICAL RESULTS D. Thioly-Bensoussan (Paris, France)	17:35

SAT12.6 QUESTIONS AND ANSWERS All	17:45

SAT12.7 LAST TRENDS AND CONCLUSION M. Gold (Nashville, USA)	18:05

SAT13 – SANOFI PASTEUR MSD
WIDER BENEFITS THAN THE PREVENTION OF CERVICAL CANCER? PRIMARY PREVENTION OF CERVICAL CANCER AND OTHER HPV RELATED DISEASES
- A REALITY DELIVERED BY GARDASIL®
Chair: G. Gross (Germany)

SAT13.1 BURDEN OF HPV RELATED DISEASES
C. Lacey (United Kingdom)

SAT13.2 THE BIOLOGY OF HUMAN PAPILLOMAVIRUS INFECTION, THE IMMUNOBIOLOGY OF DISEASE AND VACCINATION
J. Doorbar (United Kingdom)

SAT13.3 GARDASIL®: SETTING THE STANDARD FOR HPV VACCINES
N. Muñoz (Colombia)

SAT13.4 GARDASIL®: SAFETY PROFILE - FROM CLINICAL TRIALS TO POST MARKETING SURVEILLANCE
J. Monsonego (France)

SAT14 – STIEFEL
TAKING ACNE AT FACE VALUE
Chair: M. Picardo (Italy)

SAT14.1 OPENING REMARKS M. Picardo (Italy)	16:45

SAT14.2 CURRENT CHALLENGES IN ACNE TREATMENT T. Chu (United Kingdom)	17:00

SAT14.3 THE HIDDEN FACE OF ACNE: PSYCHOLOGICAL ASPECTS OF THE DISEASE L. Kircik (USA)	17:20

SAT14.4 FACING THE FUTURE: TOPICAL TREATMENT OF ACNE T. Jansen (Germany)	17:40

SAT 14.5 QUESTIONS AND CLOSING REMARKS	18:00

SAT15 – WYETH
SHAPING THE FUTURE OF PSORIASIS MANAGEMENT
Chair: P. Joly (Rouen, France)

SAT15.1 ADVANCES IN PSORIASIS AWARDS PRESENTATION
J. Prinz (Munich, Germany)

SAT15.2 MANAGING THE BROADER SYMPTOMS OF MODERATE-TO-SEVERE PSORIASIS
H. Bachelez (Paris, France)

SAT15.3 TREATMENT CHALLENGES IN THE MANAGEMENT OF CHILDHOOD PSORIASIS
A. Gottlieb (Boston, USA)
R. Langley (Nova Scotia, Canada)

Friday September 19, 2008 – 13:30 – 14:30 - Room 243

SAT16 – BEIERSDORF AG
SKIN AND AEROALLERGENS: NEW CONCEPTS AND INSIGHTS
Chair: J.P. Ortonne (Nice, France)

SAT16.1 WELCOME & INTRODUCTION J.P. Ortonne (Nice, France)	13:30

SAT16.2 CURRENT ALLERGOLOGICAL RESEARCH AREAS T. Zuberbier (Berlin, Germany)	13:40

SAT16.3 AEROALLERGENS AND SKIN – PENETRATION, RELEVANCE AND NOVEL MODES OF PROTECTION J. Lademann (Berlin, Germany)	14:00

SAT16.4 QUESTIONS & DISCUSSION 14:20 SAT16.5 CLOSING REMARKS J.P. Ortonne (Nice, France)	14:25

SAT17 – JOHNSON & JOHNSON CONSUMER FRANCE- ROC
SCIENTIFIC ADVANCES IN THE MANAGEMENT OF SKIN AGING
Co- Chairs : A. Boer Kimball (Boston, USA), J. J. Voorhees (Ann Arbor, Michigan USA)

SAT17.1 OPENING REMARKS, PROGRAM OVERVIEW, FACULTY INTRODUCTIONS	13:30

SAT17.2 SKIN-AGING: WHAT’S NEW A. Boer Kimball (Boston, USA)	13:35

SAT17.3 EFFECTIVE THERAPY FOR NATURALLY AGING SKIN J. J. Voorhees (Ann Arbor, USA)	13:55

SAT17.4 ENHANCING THE EFFECTS OF ANTI-AGING INGREDIENTS	14:15

SAT17.5 QUESTION AND ANSWER SESSION All	14:25

SAT18 – INTENDIS GMBH
OPTIMIZED TREATMENTS IN ATOPIC DERMATITIS – AN UPDATE AND OUTLOOK
Chair: T. Ruzicka (Munich, Germany)

SAT18.1 WELCOME
T. Ruzicka (Munich, Germany)

SAT18.2 TREATMENT SUCCESS FACTORS: WHAT MAKES A DIFFERENCE?
T. Ruzicka (Munich, Germany)

SAT18.3 MPA: NEW FINDINGS AND CLINICAL RESULTS
T. Luger (Munster, Germany)

SAT18.4 NEXT GENERATION: INNOVATIVE THERAPIES
T. Schwarz (Kiel, Germany)

SAT19 – LABORATOIRES DERMATOLOGIQUES AVENE
HYALURONATES: FILLERS AND MORE
Chair: J.H. Saurat (Geneva, Switzerland)

SAT19.1 HYALURONATES AND SKIN AGEING
J.H. Saurat (Geneva, Switzerland)

SAT19.2 SYNERGISTIC EFFECTS OF HYALURONATES AND RETINOIDS.
G. Kaya (Geneva, Switzerland)

SAT19.3 HYALURONATE FILLERS. STATE OF THE ART AND QUESTIONS FOR THE FUTURE.
A. Ogilvie (Erlangen, Germany)

SAT19.4 MODULATION OF HYALURONATE FILLERS OUTCOME BY SUBSEQUENT TOPICAL APPLICATION OF CD44 MODULATORS. CLINICAL AND BIOMETROLOGICAL ASSESSMENT.
A. M. Schmitt (Toulouse, France)

SAT20 – ASTELLAS
ARE WE PROVIDING OUR ATOPIC DERMATITIS PATIENTS WITH OPTIMAL THERAPY ?
C hair: C. Paul (France)

SAT20.1 WELCOME AND INTRODUCTION
C. Paul (France)

SAT20.2 THE CHALLENGE
T. Bieber (Germany)

SAT20.3 WHY WE NEED A DIFFERENT APPROACH
M. Cork (United Kingdom)

SAT20.4 NEW INSIGHTS FOR BETTER PATIENT OUTCOMES
S. Reitamo (Finland)

SAT20.5 CLOSING REMARKS
C. Paul (France)

Q&A

SAT21 – INTENDIS
5-ALA PATCH-PDT OF ACTINIC KERATOSIS: A REAL INNOVATION
Chair : L. Braathen (Bern, Switzerland)
Co-Chair : R. M. Szeimies (Regensburg, Germany)

SAT21.1 - WELCOME AND INTRODUCTION L. Braathen (Bern, Switzerland)	13:30

SAT21.2 - CURRENT PDT MODALITIES FOR THE TREATMENT OF ACTINIC KERATOSIS C. Morton (Stirling, United Kingdom)	13:35

SAT21.3 - APPLICATION DURATION OF A NOVEL 5-ALA PATCH DETERMINES FLUORESCENCE INTENSITY AND EFFICACY IN PDT OF ACTINIC KERATOSIS P.Mohr (Buxtehude, Germany)	13:45

SAT21.4 - 5-ALA PATCH-PDT PROVES SUPERIOR TO PLACEBO-PDT IN TREATING ACTINIC KERATOSIS IN A DOUBLE-BLIND SETTING A. Hauschild (Kiel, Germany)	13:55

SAT21.5 - 5-ALA PATCH-PDT IS MORE EFFICACIOUS IN TREATING ACTINIC KERATOSIS THAN CRYOSURGERY AND WITH BETTER COSMETIC OUTCOME R. M. Szeimies (Regensburg, Germany)	14:10

SAT21.6 - CLOSING REMARKS L.Braathen (Bern, Switzerland)	14:25

Friday September 19, 2008 – 16:45 – 18:15 - Room 242 AB

SAT22 – JANSSEN-CILAG
THE CHANGING PARADIGM OF PSORIASIS AND ITS TREATMENT
Chair: C. Griffiths (Manchester - United Kingdom)
Co-Chair: J. P. Ortonne (Nice - France)

SAT22.1 INTRODUCTION: IMPROVED UNDERSTANDING OF THE PATHOPHYSIOLOGY OF PSORIASIS IS DRIVING THE DEVELOPMENT OF INNOVATIVE BIOLOGIC THERAPIES C. Griffiths (Manchester - United Kingdom) J. P. Ortonne (Nice - France)	16:45

SAT22.2 FROM BENCH TO BEDSIDE - TRANSLATIONAL RESEARCH IN PSORIASIS J. Prinz (munich, Germany)	16:55

SAT22.3 NEW BIOLOGIC THERAPIES IN DEVELOPMENT TARGETING IL-12/IL-23 P. Van de Kerkhof (Nijmegen - The Netherlands)	17:15

SAT22.4 COMPARING BIOLOGIC THERAPIES IN PSORIASIS - IMPLICATIONS FOR CLINICAL PRACTICE C. Griffiths (Manchester - United Kingdom)	17:35

Q&A	18:05

SAT23 – IBSA INSTITUT BIOCHIMIQUE SA / LABORATOIRES GENEVRIER
THE IMPACT OF PSORIASIS ON QUALITY OF LIFE: THE GOAL OF A MODERN THERAPEUTIC APPROACH
Chair: L. Dubertret (France)

SAT23.1 WELCOME AND INTRODUCTION	16:45

SAT23.2 IMPACT ON QUALITY OF LIFE OF COMMON DERMATOLOGICAL CONDITIONS J. Hercogova (Czech Republic)	16:50

SAT23.3 ROLE OF TOPICAL CORTICOSTEROIDS IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS M. Esposito (Italy)	17:10

SAT23.4 IMPROVED SAFETY AND EFFICACY OF A NEW TOPICAL FORMULATION CONTAINING BMV L. Kemeny (Hungary)	17:25

SAT23.5 FROM CLINICS TO MEDICAL PRACTICE: CASE HISTORIES FROM SLOVAK REPUBLIC H. Zelenková (Slovak Republic)	17:45

SAT23.6 DISCUSSION AND CONCLUSION	17:55

SAT24 – MERCK SERONO
RAPTIVA® : A TRUSTED THERAPY FOR ENDURING DISEASE REDUCTION OF PSORIASIS
Chair : P. Joly (Rouen, France)

SAT24.1 PSORIASIS AS A CHRONIC INFLAMMATORY SYSTEMIC DISEASE (CISD)
D. Jullien (Lyon, France)

SAT24.2 CARDIO-METABOLIC CO-MORBIDITIES AND PSORIASIS
W. P. Gulliver (Newfoundland, Canada)

SAT24.3 LONG TERM CLINICAL DATA ABOUT EFALIZUMAB: 2243 AND CONTROL II
M. Bagot (Créteil, France)

SAT24.4 PHARMACOGENOMICS: GETTING CLOSER TO A TAILORED THERAPY?
A. Costanzo (Roma, Italy)

SAT25 – THERMAGE INC
THE GOLD STANDARD IN RADIOFREQUENCY
Chair: M. Mavridou (Greece)

SAT26 – PIERRE FABRE DERMATOLOGIE
SKIN BARRIER DISORDERS
Chair: C. Blanchet-Bardon (Paris, France)

SAT26.1 WELCOME AND INTRODUCTION C. Blanchet-Bardon (Paris, France)	16:45

SAT26.2 ICHTHYOSIS VULGARIS: A MODEL FOR EPIDERMAL BARRIER DISEASES H. Traupe (Muenster, Germany)	16:50

SAT26.3 ATOPIC DERMATITIS : PATHOPHYSIOLOGY AND MANAGEMENT G. Tadini (Milano, Italy)	17:05

SAT26.4 CONGENITAL ICHTYOSIS : TOPICAL AND SYSTEMIC TREATMENT OVERVIEW J. Mazereeuw-Hautier (Toulouse, France)	17:20

SAT26.5 EFFECTIVENESS AND SAFETY OF AN EMOLLIENT CREAM IN THE TREATMENT OF ICHTHYOSIS IN CHILDREN : RESULTS OF AN INTERNATIONAL MULTICENTRIC RANDOMISED CONTROLLED DOUBLE BLIND STUDY C. Blanchet-Bardon (Paris, France)	17:35

SAT26.6 QUESTIONS AND ANSWERS All	17:50

SAT26.7 CLOSING REMARKS C. Blanchet-Bardon (Paris, France)	18:10

Saturday September 20, 2008 – 13:00 – 14:30

SAT27 – INTERNATIONAL PSORIASIS COUNCIL
IPC MEET THE EXPERTS CASE-BASED LEARNING FORUM
Chair: W. Sterry (Berlin, Germany)

Panelists:
J. Barker (London, United Kingdom)
S. Chimenti (Roma, Italy)
P. Van de Kerkhof (Nijmegen, The Netherlands)